Zongmuyu Zhang

Zongmuyu Zhang

Auto-generated profile, based on publicly available information

Zongmuyu Zhang

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
EGEnying Gong
Enying Gong
ZZZongmuyu Zhang
Zongmuyu Zhang
XJXurui Jin
Xurui Jin
YLYishan Liu
Yishan Liu
LZLumin Zhong
Lumin Zhong
BOBrian Oldenburg
Brian Oldenburg
Background: The emergence and advancement of mobile technologies offer a promising opportunity for people with diabetes to improve their self-management. Despite the proliferation of mobile apps, few studies have evaluated the apps that are available to the millions of people with diabetes in China. Objective: This study aimed to conduct a systematic search of Chinese mobile apps for diabetes self-management and to evaluate their quality, functionality, and features by using validated rating scales. Methods: A systematic search was conducted to identify Chinese apps for diabetes self-management in the four most popular Chinese language mobile app stores. Apps were included if they were designed for diabetes self-management and contained at least one of the following components: blood glucose management, dietary and physical activity management, medication taking, and prevention of diabetes-related comorbidities. Apps were excluded if they were unrelated to health, not in Chinese, or the targeted users are health care professionals. Apps meeting the identified inclusion criteria were downloaded and evaluated by a team of 5 raters. The quality, functionalities, and features of these apps were assessed by using the Mobile App Rating Scale (MARS), the IMS Institute for Healthcare Informatics Functionality score, and a checklist of self-management activities developed based on the Chinese diabetes self-management guideline, respectively. Results: Among 2072 apps searched, 199 were eligible based on the inclusion criteria, and 67 apps were successfully downloaded for rating. These 67 apps had an average MARS score of 3.42 out of 5, and 76% (51/67) of the apps achieved an acceptable quality (MARS score >3.0). The scores for the four subdomains of MARS were 3.97 for functionality, 3.45 for aesthetics, 3.21 for information, and 3.07 for engagement. On average, reviewed apps applied five out of the 19 examined behavior change techniques, whereas the average score on the subjective quality for the potential impact on behavior change is 3 out of 5. In addition, the average score on IMS functionality was 6 out of 11. Functionalities in collecting, recording, and displaying data were mostly presented in the reviewed apps. Most of the apps were multifeatured with monitoring blood glucose and tracking lifestyle behaviors as common features, but some key self-management activities recommended by clinical guidelines, such as stress and emotional management, were rarely presented in these apps. Conclusions: The general quality of the reviewed apps for diabetes self-management is suboptimal, although the potential for improvement is significant. More attention needs to be paid to the engagement and information quality of these apps through co-design with researchers, public health practitioners, and consumers. There is also a need to promote the awareness of the public on the benefit and potential risks of utilizing health apps for self-management.

1 March 2022 in Fundamental Research
Verified
Journal Article
Open access
YCYuwen Chen
Yuwen Chen
JLJia Liu
Jia Liu
MLMingli Li
Mingli Li
YYYannan Yu
Yannan Yu
ZYZhengzheng Yan
Zhengzheng Yan
WXWeihai Xu
Weihai Xu
In vivo studies on association between wall shear stress (WSS) and intracranial plaque are deficient. Based on the three-dimensional T1-weighted high-resolution magnetic resonance imaging (3DT1 HR-MRI) data of patients with low-grade stenotic (<50%) atherosclerotic middle cerebral artery (MCA) and subjects with normal MCA, we built a three-dimensional reconstructed WSS model by computational fluid dynamics (CFD) technique. Three-dimensional registration of the CFD model to the HR-MRI was performed with projections based on the resolution and thickness of the images. The relationships between the WSS at each side of the vessel wall and plaque location were analyzed. A total of 94 MCA plaques from 43 patients and 50 normal MCAs were analyzed. In the normal MCAs, WSS was lower at the ventral-inferior wall than at the dorsal-superior wall (proximal segment, p < 0.001; middle segment, p < 0.001) and lower at the inner wall than at the outer wall of the MCA curve (p < 0.001). In atherosclerotic MCAs, similar low WSS regions were observed where plaques developed. The WSS ratio of the ventral-inferior wall to the dorsal-superior wall in atherosclerotic MCAs was lower than that in normal MCAs (p = 0.002). The WSSinner-outer ratio in atherosclerotic MCAs was lower than that in normal MCAs (p = 0.002). Low WSS was associated with MCA atherosclerosis formation and occurred mainly at the ventral-inferior wall, which was anatomically opposite the orifices of penetrating arteries, and at the inner wall of the MCA curve. Overall, the results were well consistent with the low WSS theory in atherosclerosis formation. The reconstructed WSS model is a promising novel method for assessing an individualized vascular profile once validated by further studies.

15 August 2024 in International Journal of Stroke
Verified
Journal Article
Closed access
XHXinzhi Hu
Xinzhi Hu
ZZZongmuyu Zhang
Zongmuyu Zhang
CLCaiyan Liu
Caiyan Liu
MLMingli Li
Mingli Li
YLYiyang Liu
Yiyang Liu
WXWei-Hai Xu
Wei-Hai Xu
Rationale: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors enable an additional 54–75% reduction in low-density lipoprotein cholesterol (LDL-C) in statin-treated patients, demonstrating plaque regression in coronary artery disease. However, the impact of achieving an extremely low level of LDL-C with PCSK9 inhibitors (e.g. Evolocumab) on symptomatic intracranial atherosclerosis remains unexplored. Aim and hypothesis: To determine whether combining Evolocumab and statins achieves a more significant symptomatic intracranial plaque regression than statin therapy alone. Sample size estimates: With a sample size of 1000 subjects, a two-sided α of 0.05, and 20% lost to follow-up, the study will have 83.3% power to detect the difference in intracranial plaque burden. Methods and design: This is an investigator-initiated multicenter, randomized, open-label, outcome assessor-blinded trial, evaluating the impact of combining Evolocumab and statins on intracranial plaque burden assessed by high-resolution magnetic resonance imaging at baseline in patients undergoing a clinically indicated acute stroke or transient ischemic attack due to intracranial artery stenosis, and after 24 weeks of treatment. Subjects (n = 1000) were randomized 1:1 into two groups to receive either Evolocumab 140 mg every 2 weeks with statin therapy or statin therapy alone. Study outcomes: The primary endpoint is the change in intracranial plaque burden assessed by high-resolution magnetic resonance imaging, performed at baseline and at the end of the 24-week treatment period. Discussion: This trial will explore whether more significant intracranial plaque regression is achievable with the treatment of combining Evolocumab and statins, providing information about efficacy and safety data. Trial registration number: ChiCTR2300068868; https://www.chictr.org.cn/

18 August 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
XHXinzhi Hu
Xinzhi Hu
YLYiyang Liu
Yiyang Liu
WYWeizhuang Yuan
Weizhuang Yuan
ZZZongmuyu Zhang
Zongmuyu Zhang
SLShun Li
Shun Li
WXWeihai Xu
Weihai Xu
Background: We aimed to investigate the effects of evolocumab, a proprotein convertase subtilisin/kexin type‐9 inhibitor for intensive lipid‐lowering, on intracranial atherosclerotic stenosis. Methods: From a prospectively established high‐resolution magnetic resonance imaging database, consecutive patients with intracranial atherosclerotic stenosis (≥50%) with 2 detections of high‐resolution magnetic resonance imaging over 6 months were included in this retrospective analysis. Eligible patients were grouped by treatment: evolocumab add‐on (evolocumab + ) versus no evolocumab (evolocumab − ). The primary outcome was plaque response (plaque regression >5%). Secondary outcomes included the percentage of changes in plaque burden and stenosis degree. Logistic and linear regression analyses were used to estimate the association between evolocumab use and the above outcomes in both the general and subgroup (intensive versus nonintensive statin) analyses. Results: Among 179 statin‐treated patients (50 evolocumab + , 129 evolocumab − ), evolocumab add‐on therapy was associated with higher plaque response (68.0% versus 34.1%), greater plaque burden reduction (median [interquartile range]: −8.2% [−11.4%, −1.8%] versus –1.9% [−6.7%, 4.4%]), and stenosis degree reduction (−15.3% [−33.7%, −1.3%] versus –5.4% [−25.8%, 12.3%]). Adjusted regression analyses showed significant associations between evolocumab use and plaque response (odds ratio [95% CI], 6.67 [2.80, 16.91]), plaque burden reduction (estimate [95% CI], −7.0% [−11.5%, −2.5%]), and stenosis degree reduction (estimate [95% CI], −20.3% [−31.7%, −7.0%]). Subgroup analyses according to background statin intensity showed consistent associations. Conclusions: Evolocumab add‐on therapy over 6 months was associated with intracranial atherosclerotic plaque regression compared with statin therapy alone. However, given the retrospective design and potential between‐group differences, these findings require further confirmation in prospective randomized controlled studies.